Behavioural Pharmacology
June 1, 2025
Ronan Depoortère, Mariusz Papp, Piotr Gruca et al.
2 citations
Ketamine displays efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model. It rapidly reverses anhedonia (CMS-induced sucrose consumption deficit) and attenuates working memory deficit (novel object recognition: NOR) following both systemic (intraperitoneal, i.p.) administration or local administration in the prefrontal cortex (PFC). However, the...
Journal of Psychopharmacology
July 1, 2024
Mariusz Papp, Piotr Gruca, Ewa Litwa et al.
15 citations
The highly selective 5-HT1A serotonin receptor "biased" agonists NLX-101 and NLX-204 display, like ketamine, potent and efficacious rapid-acting antidepressant (RAAD) activity in the rat chronic mild stress (CMS) model with systemic (i.p.) administration. They rapidly (within 1 day) reverse anhedonia (i.e., CMS-induced sucrose consumption deficit), attenuate working memory deficit (novel object...
Psychopharmacology
June 13, 2023
Mariusz Papp, Piotr Gruca, Magdalena Lason et al.
NLX-101 and NLX-204 are highly selective serotonin 5-HT1A ‘biased’ agonists, displaying potent and efficacious antidepressant-like activity upon acute administration in models such as the forced swim test. we compared the effects of repeated administration of NLX-101, NLX-204 and ketamine in the chronic mild stress (CMS) model of depression, considered to have high translational potential, on...
Behavioural Pharmacology
February 2017
Mariusz Papp, Piotr Gruca, Magdalena Lason-Tyburkiewicz et al.
Ketamine is the prototype of a new generation of antidepressant drugs, which is reported in clinical studies to be effective in treatment-resistant patients, with an effect that appears within hours and lasts for a few days. Chronic mild stress (CMS) is a well-established and widely used animal model of depression, in which anhedonia, anxiogenesis and cognitive dysfunction can be observed...